This HTML5 document contains 272 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://dx.doi.org/10.1038/
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36946580
rdf:type
wikibase:Item
schema:description
artigo científico teaduslik artikkel scienca artikolo vědecký článek 2007年论文 tieteellinen artikkeli vetenskaplig artikel artikull shkencor artigo científico ২০ সেপ্টেম্বর ২০০৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ บทความทางวิทยาศาสตร์ scientific article published on 20 September 2007 vitenskapelig artikkel vedecký článok 2007 nî lūn-bûn научная статья 2007년 논문 2007年論文 מאמר מדעי scientific article published on 20 September 2007 наукова стаття, опублікована у вересні 2007 vitskapeleg artikkel научни чланак article scientifique مقالة علمية نشرت في 20 سبتمبر 2007 2007年论文 2007年論文 2007年论文 επιστημονικό άρθρο 2007年論文 2007年论文 article científic tudományos cikk სამეცნიერო სტატია wissenschaftlicher Artikel artigo científico articolo scientifico artículo científico publicado en 2007 artikel ilmiah научна статия naučni članak bilimsel makale articol științific 2007年論文 artículu científicu espublizáu en 2007 artikulong pang-agham artykuł naukowy мақолаи илмӣ scientific article published on 20 September 2007 bài báo khoa học 2007年の論文 научни чланак 2007年论文 article scientific videnskabelig artikel 2007年論文 2007年论文 wetenschappelijk artikel
p:P577
wds:Q36946580-28186AA3-065E-4E90-8017-77AB111F5665
wdt:P577
2007-09-20T00:00:00Z
p:P2888
wds:Q36946580-9A2F520D-6DC6-41F0-AF67-9576D242EAD6
wdt:P2888
n11:sj.leu.2404948
p:P2860
wds:Q36946580-F86850FA-7B06-4DCB-AB86-4087EB0899AB wds:Q36946580-FA74B874-E0F2-47AD-9326-EFD8EBE50E3F wds:Q36946580-FCC57FCE-5244-4865-B842-F36C6812DAA9 wds:Q36946580-FF5EA071-9D85-45B3-B2BC-74FF0A1030C6 wds:Q36946580-D7CD3101-D1C8-442B-8BDE-6743A6FC6480 wds:Q36946580-D88670CD-1CE1-4284-9FE2-BD05FBC35DFB wds:Q36946580-D937145C-C44E-4CD4-8154-BC04C7E96417 wds:Q36946580-DC339F88-BC17-40D8-BFDA-A00D0F7CA4C1 wds:Q36946580-DDD1A742-1D8F-4B3C-A362-4C0A5A60DBDA wds:Q36946580-DFE080FF-BB2D-4783-AB7D-E902B083B181 wds:Q36946580-E10EDA3F-32E9-482B-B3EB-4BE0AFB1B7F9 wds:Q36946580-E25353D9-E653-4133-9BD1-1C612BD48477 wds:Q36946580-E3A1746C-E863-4D9F-9418-42CD9C5B7AC1 wds:Q36946580-E8B7F90C-F485-40C5-8835-DE197BDCCD11 wds:Q36946580-EB7B72D9-033E-4923-8505-146DF811D3CC wds:Q36946580-ECD64156-281D-446B-955D-905CB3ED9243 wds:Q36946580-F1BB8A76-9DD5-435E-A528-6B45E2E11A94 wds:Q36946580-F64AED18-CEB4-4A7C-A57C-850EDC1A2176 wds:Q36946580-4EDAE7AA-24E0-4013-AD32-22342BB7377A wds:Q36946580-53DBFFC8-BF9A-42B8-A89C-C278121A0454 wds:Q36946580-59952455-5B95-4B95-8D6D-C7EEDB0F05E4 wds:Q36946580-5B074B83-778B-4170-BF5A-47BDD6EEE860 wds:Q36946580-5B982D49-2C4B-466B-8799-877BF497B65F wds:Q36946580-5C1736FA-CF35-47DA-91AE-42A979D98E43 wds:Q36946580-5D7F38D5-DBCA-4016-8545-3D3FFAF4DEAE wds:Q36946580-5F8F91DB-7529-40EC-A26F-1A65D1C0E4F2 wds:Q36946580-5FAA928B-238E-4617-B211-D69C39AD57CE wds:Q36946580-6E77B766-F3CA-4962-A82F-C9EB6740243D wds:Q36946580-77438DC2-844F-41ED-9AB3-C4A8137345D7 wds:Q36946580-7798BB91-72DC-4F57-8103-7BC5F7536B18 wds:Q36946580-7A5CB932-8181-4E69-B9DE-AAABBA059769 wds:Q36946580-7C4B3426-FB45-4DB4-8802-4E4ED1C60298 wds:Q36946580-84E3C72E-8480-481B-8E0A-30EA108C8626 wds:Q36946580-301AF798-4598-4A40-A7CC-01C8FD77F1A3 wds:Q36946580-3363659E-8048-4557-82C1-A9205EFEE74C wds:Q36946580-3B4FE821-0C5A-4DDE-824F-817BF2B83382 wds:Q36946580-3D717441-F1A0-4D3B-9AA1-8159EAF6BE13 wds:Q36946580-3EBAC283-67D9-45B2-8EA6-7A04B1E1DE08 wds:Q36946580-40E13BDF-CC31-41A6-9689-E59A1792E4AB wds:Q36946580-421F7226-12DE-49F5-9683-B68CF2B9BEEF wds:Q36946580-4345A12A-0E7D-469D-82F9-972B611DADEA wds:Q36946580-47D23BE0-D296-45EB-956E-1F63A25E61A4 wds:Q36946580-47E312A7-A6DE-4479-9A1E-8913652454A3 wds:Q36946580-4862147C-C47E-4112-8EBC-9BE617AD0D87 wds:Q36946580-4DCEFC36-5DEC-407A-98FA-91CFCA02D3B7 wds:Q36946580-4ECBC6A9-5AC8-4FF4-BD91-E94411D50F65 wds:Q36946580-AD260970-A3B1-49CC-AE9C-FDE8913C3809 wds:Q36946580-AD372466-3B58-4D0A-B8E6-ED5D265ED451 wds:Q36946580-B3819BAB-D5BB-4404-9630-5093E916B099 wds:Q36946580-B5834BB4-50CE-4FAF-8138-C9F20C9AEA34 wds:Q36946580-B9E45B88-97E8-4851-B055-C2E36621CCBF wds:Q36946580-BB3CA3AB-8AEE-48F2-9604-91254EE2E553 wds:Q36946580-C57A435E-D27E-4AF5-997D-4160DE348426 wds:Q36946580-C811B7F7-BD49-45C1-ACC6-E8967825683E wds:Q36946580-CF56A38F-A21C-42B1-93B8-F0EDAB61B676 wds:Q36946580-D07E5668-248C-4E9C-9331-FD8B195FD9AA wds:Q36946580-D72760B0-7632-4035-AA56-074C768001FE wds:Q36946580-84F1A812-A8C0-4197-AECA-469E1C9DB94D wds:Q36946580-88AB385F-DF9C-40BA-BB1D-E7668EF8088D wds:Q36946580-8A83462F-9B88-4774-ADC9-5780A062BB2E wds:Q36946580-8A975101-3988-486B-B727-EE3FAB34C8ED wds:Q36946580-8AED49CE-CF1B-4CA7-9CF3-8B87D6F381A0 wds:Q36946580-8C475857-2C29-4CAF-B215-6CBECC2DA86F wds:Q36946580-8F8E2441-F764-4B32-AA87-E5C802B0EA5D wds:Q36946580-9B655FF5-CC1B-4D54-B4E4-714858DEF5FF wds:Q36946580-9CD76778-D6F1-40E6-A579-403E210ED413 wds:Q36946580-9F3969A9-BD86-4103-8943-28F1657B2624 wds:Q36946580-A170B33B-7F73-4D2E-A990-D5B56BA21242 wds:Q36946580-A17EFE46-D8FD-4F7D-AD16-8D596F7C9E85 wds:Q36946580-A3B96E32-F66B-41EC-BBC1-B5774A84D299 wds:Q36946580-A3BA5871-8C6C-43E0-BC6D-852ADA25D8BE wds:Q36946580-A41D06D1-3B67-4A72-8E26-AF16CCA965AC wds:Q36946580-05462443-6B8D-4E5E-B543-328957907BCA wds:Q36946580-098C49FE-9F01-4313-BE34-D63F2E1733B2 wds:Q36946580-0A840834-B19D-43A2-A009-990BFB5A2936 wds:Q36946580-0E9EB880-863A-4C58-AE5C-26E42A06184F wds:Q36946580-0F380C07-A930-4E8D-9FBE-C5EC1AD767C4 wds:Q36946580-11DB0953-929C-418D-8835-EDB39DDF2BD7 wds:Q36946580-1203C009-184C-41D0-B283-56FB3B0668D8 wds:Q36946580-1B01A114-7DE5-4DEE-BF65-4A0D0E378B89 wds:Q36946580-1BE49DC7-89A4-49B3-8CD4-D37A1949BE6E wds:Q36946580-1D06B797-E09E-4C90-A969-D11B0768AD79 wds:Q36946580-2373A484-D2D9-45BA-9902-A5BFE9F01CA8 wds:Q36946580-2858D564-EDA5-43A1-8AEA-7AF78C371E26 wds:Q36946580-2B42343D-EADC-4C9F-BBD9-0EE8EC6538CB wds:Q36946580-2ED357BA-A311-44C6-953A-EEE239F5F115 wds:Q36946580-00091F24-ACA8-4164-ACB7-3865F3CB4E45
wdt:P2860
wd:Q80575698 wd:Q24609999 wd:Q34300737 wd:Q71629137 wd:Q42109929 wd:Q34412332 wd:Q29614337 wd:Q45061834 wd:Q40255542 wd:Q34179968 wd:Q80070172 wd:Q43031345 wd:Q79157567 wd:Q46428222 wd:Q80050823 wd:Q24316448 wd:Q29618853 wd:Q45278082 wd:Q40760923 wd:Q53544139 wd:Q44854570 wd:Q28253771 wd:Q38301968 wd:Q33947635 wd:Q29618851 wd:Q53588179 wd:Q80312874 wd:Q71542089 wd:Q28277030 wd:Q36468734 wd:Q35848032 wd:Q44695040 wd:Q40235276 wd:Q44639305 wd:Q70220517 wd:Q34549807 wd:Q33906140 wd:Q71206377 wd:Q27266125 wd:Q27824808 wd:Q35849674 wd:Q57054898 wd:Q35849213 wd:Q50727065 wd:Q40235023 wd:Q40444894 wd:Q83854576 wd:Q36668207 wd:Q28217482 wd:Q29614280 wd:Q43948616 wd:Q44451881 wd:Q80220582 wd:Q58289362 wd:Q46713383 wd:Q51761197 wd:Q44008600 wd:Q28270987 wd:Q34633315 wd:Q40200859 wd:Q37044312 wd:Q82828367 wd:Q33889476 wd:Q46849974 wd:Q50721189 wd:Q80195293 wd:Q28241887 wd:Q79434773 wd:Q81321013 wd:Q40643306 wd:Q24685474 wd:Q33370821 wd:Q73812277 wd:Q79777413 wd:Q28295823 wd:Q28214721 wd:Q34512051 wd:Q34770384 wd:Q29547900 wd:Q40420997 wd:Q27824871 wd:Q41743756 wd:Q40746470 wd:Q33371084 wd:Q79390658 wd:Q34468309 wd:Q35848319
p:P2093
wds:Q36946580-01759F30-9EE2-424F-AAFE-487596157010
wdt:P2093
Pardanani A
rdfs:label
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
skos:prefLabel
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
schema:name
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
p:P1476
wds:Q36946580-F3C8A9F2-B47B-4BFD-A960-79CF90266CBA
wdt:P1476
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
p:P304
wds:Q36946580-35DDE22B-2161-4317-918E-83AABA0FEBA5
wdt:P304
23-30
p:P31
wds:Q36946580-5be216e0-05fd-4ad1-92fa-3b99502a0201 wds:Q36946580-F21B7B5E-F5E8-4E7F-9524-C78E9428C095
wdt:P31
wd:Q13442814 wd:Q7318358
p:P921
wds:Q36946580-CB249E4E-3227-47AB-BA36-A9A4E2098F41
wdt:P921
wd:Q1898104
p:P698
wds:Q36946580-AC173B20-6BD0-4D34-B5BA-0FF16121A9D4
wdtn:P698
n10:17882282
wdt:P698
17882282
p:P1433
wds:Q36946580-4494EBFD-CD61-4F41-8F1F-ABF1E8A7A399
wdt:P1433
wd:Q6534498
p:P433
wds:Q36946580-410166D7-BF25-411A-8E95-7DDDCAF7BAF8
p:P478
wds:Q36946580-C5C992D4-ED70-48D2-A40B-677870571951
wdt:P433
1
wdt:P478
22
p:P356
wds:Q36946580-D17C8416-A6E4-4A6B-B872-58C75B6F0ABC
wdtn:P356
n13:SJ.LEU.2404948
wdt:P356
10.1038/SJ.LEU.2404948
p:P5875
wds:Q36946580-C38E7CE4-CD38-40C1-ADDA-0071DABB02D7
wdt:P5875
5961372